Snowden Capital Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History

Snowden Capital Advisors’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$454K	Buy	4,155 +615	+17%	+$63.7K	0.01%	880
2026 Q1	$368K	Buy	+3,540	New	+$377K	0.01%	937
2022 Q1	–	Sell	-100	Closed	-$7K	–	1799
2021 Q4	$7K	Buy	+100	New	+$7.44K	﹤0.01%	1616

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Snowden Capital Advisors's PPH Position: Q2 2026 in Review

Snowden Capital Advisors increased its VanEck Pharmaceutical ETF (PPH) stake by 17% in Q2 2026, buying an estimated $63.7K and bringing the position to 4,155 shares worth $454K. The position accounts for 0.01% of the portfolio, ranked #880.

Snowden Capital Advisors first reported a position in PPH in Q4 2021 and has held it in 3 quarters since. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

Snowden Capital Advisors held 4,155 shares of VanEck Pharmaceutical ETF worth $454K as of Q2 2026.
Snowden Capital Advisors bought 615 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $63.7K.
VanEck Pharmaceutical ETF made up 0.01% of Snowden Capital Advisors's portfolio in Q2 2026, its #880 holding.
Snowden Capital Advisors first reported a position in VanEck Pharmaceutical ETF in Q4 2021 and has held it in 3 quarters since.
148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.